Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

Eli Lilly and Company LLY is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, ...

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

A new overview details emerging medical and wellness trends, underscoring advances that broaden treatment access and inform preventive care. GLP-1 drugs such as Ozempic and Wegovy extend to heart, ...

By Louise Rasmussen COPENHAGEN, Feb 18 (Reuters) - Denmark-based Arla expects a global milk surplus to drive down dairy ...

My son is smart - he really is - but he was in love. He and his live-in girlfriend mingled their finances. I'm not sure how much, but now that they've parted, his credit rating is wrecked. Just enough ...

A new study confirms that people taking GLP-1s are more likely to experience hair loss. The good news? It’s probably reversible. Here’s how to deal.

Eli Lilly (NYSE:LLY) is not waiting around for the green light. The company has already built up $1.5 billion worth of inventory for its oral weight-loss drug Orforglipron as it prepares for a ...